# Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors

> **NCT02836795** · PHASE1 · COMPLETED · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 35 (actual)

## Conditions studied

- Melanoma
- Urological Cancer

## Interventions

- **BIOLOGICAL:** humanized anti-PD-1 monoclonal antibody Toripalimab (JS001)

## Key facts

- **NCT ID:** NCT02836795
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2018-09
- **Final completion:** 2018-12-17
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2025-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02836795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02836795, "Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02836795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*